Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

被引：0
|
作者：
Hiroaki Seino
机构：
[1] Seino Internal Medical Clinic,
来源：
Diabetes Therapy | 2021年 / 12卷
关键词：
Hepatic dysfunction; Luseogliflozin; SGLT2 inhibitor; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：863 / 877
页数：14
相关论文
共 50 条
  • [41] An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women
    Handog, Evangeline B.
    Datuin, Maria Suzanne L.
    Singzon, Ivan A.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2016, 55 (02) : 153 - 157
  • [42] Efficacy and safety of trimethoprim-sulfamethoxazole in HIV-infected patients with cerebral toxoplasmosis in Brazil: a single-arm open-label clinical trial
    Pellegrino, Daniela
    Gryschek, Ronaldo
    Penalva de Oliveira, Augusto Cesar
    Marcusso, Rosa
    Correia, Ademir
    Vidal, Jose E.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2019, 30 (12) : 1156 - 1162
  • [43] A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)
    Zhang, Fengkui
    Peng, Guangxin
    He, Guangsheng
    Chang, Hong
    Gao, Sujun
    Liu, Xinjian
    Chen, Tong
    Li, Pei
    Han, Bing
    Miao, Miao
    Ge, Zheng
    Ge, Xiaoyan
    Li, Fei
    Li, Yingmei
    Wang, Shunqing
    Wang, Yi
    Shen, Yaqi
    Tai, Yanfei
    Zhang, Tao
    Zhu, Bo
    Zou, Jianjun
    BLOOD, 2020, 136
  • [44] Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
    Yang, Dawei
    Ju, Minjie
    Wang, Hao
    Jia, Yichen
    Wang, Xiaodan
    Fang, Hao
    Fan, Jia
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [45] Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
    Dawei Yang
    Minjie Ju
    Hao Wang
    Yichen Jia
    Xiaodan Wang
    Hao Fang
    Jia Fan
    BMC Pharmacology and Toxicology, 24
  • [46] Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
    Marron, Thomas U.
    Fiel, Maria Isabel
    Hamon, Pauline
    Fiaschi, Nathalie
    Kim, Edward
    Ward, Stephen C.
    Zhao, Zhen
    Kim, Joel
    Kennedy, Paul
    Gunasekaran, Ganesh
    Tabrizian, Parissa
    Doroshow, Deborah
    Legg, Meredith
    Hammad, Ashley
    Magen, Assaf
    Kamphorst, Alice O.
    Shareef, Muhammed
    Gupta, Namita T.
    Deering, Raquel
    Wang, Wei
    Wang, Fang
    Thanigaimani, Pradeep
    Mani, Jayakumar
    Troncoso, Leanna
    Tabachnikova, Alexandra
    Chang, Christie
    Akturk, Guray
    Buckup, Mark
    Hamel, Steven
    Ioannou, Giorgio
    Hennequin, Clotilde
    Jamal, Hajra
    Brown, Haley
    Bonaccorso, Antoinette
    Labow, Daniel
    Sarpel, Umut
    Rosenbloom, Talia
    Sung, Max W.
    Kou, Baijun
    Li, Siyu
    Jankovic, Vladimir
    James, Nicola
    Ham, Sara C.
    Cheung, Hung Kam
    Sims, Jennifer S.
    Miller, Elizabeth
    Bhardwaj, Nina
    Thurston, Gavin
    Lowy, Israel
    Gnjatic, Sacha
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 219 - 229
  • [47] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
    Morschhauser, Franck
    Tilly, Herve
    Chaidos, Aristeidis
    McKay, Pamela
    Phillips, Tycel
    Assouline, Sarit
    Batievi, Connie Lee
    Campbell, Phillip
    Ribrag, Vincent
    Damaj, Gandhi Laurent
    Dickinson, Michael
    Jurczak, Wojciech
    Kazmierczak, Maciej
    Opat, Stephen
    Radford, John
    Schmitt, Anna
    Yang, Jay
    Whalen, Jennifer
    Agarwal, Shefali
    Adib, Deyaa
    Salles, Gilles
    LANCET ONCOLOGY, 2020, 21 (11): : 1433 - 1442
  • [48] Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
    Wang, Xuan
    Wu, Xiaowen
    Yang, Yue
    Xu, Weiran
    Tian, Hui
    Lian, Bin
    Chi, Zhihong
    Si, Lu
    Sheng, Xinan
    Kong, Yan
    Zhou, Li
    Mao, Lili
    Li, Siming
    Tang, Bixia
    Yan, Xieqiao
    Bai, Xue
    Guo, Jun
    Cui, ChuanLiang
    EUROPEAN JOURNAL OF CANCER, 2023, 182 : 57 - 65
  • [49] Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
    Yoko Edahiro
    Kohshi Ohishi
    Akihiko Gotoh
    Katsuto Takenaka
    Hirohiko Shibayama
    Takayuki Shimizu
    Kensuke Usuki
    Kazuya Shimoda
    Masafumi Ito
    Scott A. VanWart
    Oleh Zagrijtschuk
    Albert Qin
    Hiroaki Kawase
    Narihisa Miyachi
    Toshiaki Sato
    Norio Komatsu
    Keita Kirito
    International Journal of Hematology, 2022, 116 : 215 - 227
  • [50] Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial
    Kumeso, Victor Kande Betu
    Kalonji, Wilfried Mutombo
    Rembry, Sandra
    Mordt, Olaf Valverde
    Tete, Digas Ngolo
    Pretre, Adeline
    Delhomme, Sophie
    Kyhi, Medard Ilunga Wa
    Camara, Mamadou
    Catusse, Julie
    Schneitter, Stefan
    Nusbaumer, Morgane
    Miaka, Erick Mwamba
    Mbembo, Helene Mahenzi
    Mayawula, Joseph Makaya
    Camara, Mariame Layba
    Massa, Felix Akwaso
    Badibabi, Lewis Kaninda
    Bonama, Augustin Kasongo
    Lukula, Papy Kavunga
    Kalonji, Sylvain Mutanda
    Philemon, Phyll Mariero
    Nganyonyi, Ricardo Mokilifi
    Mankiara, Hugues Embana
    Nguba, Andre Asuka Akongo
    Muanza, Vincent Kobo
    Nasandhel, Ernest Mulenge
    Bambuwu, Aimee Fifi Nzeza
    Scherrer, Bruno
    Strub-Wourgaft, Nathalie
    Tarral, Antoine
    LANCET INFECTIOUS DISEASES, 2023, 23 (04): : 463 - 470
12345